Self-limited acute hepatotoxicity caused by pegvisomant

Pituitary

Volumn 14, Issue 4, 2011, Pages 371-376

  Soto Moreno, A ^a   Guerrero Vazquez R ^a   Venegas Moreno, E ^a   Palma Milla, S ^a   Castano J P ^b   Leal Cerro, A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Acromegaly; Pegvisomant; Somatostatin analogs; Toxic hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CABERGOLINE; FLUDROCORTISONE; GAMMA GLUTAMYLTRANSFERASE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5;

ACROMEGALY; ADULT; ARTICLE; CASE REPORT; COMBINATION CHEMOTHERAPY; DIABETES INSIPIDUS; DIFFERENTIAL DIAGNOSIS; DISEASE CONTROL; DISORDERS OF STEROID METABOLISM; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPERTRANSAMINASEMIA; HYPOCORTICISM; HYPOGONADISM; HYPONATREMIA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; HYPOTHYROIDISM; INJECTION SITE REACTION; LIPODYSTROPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOTACTIC BODY RADIATION THERAPY; TOXIC HEPATITIS; TRANSSPHENOIDAL HYPOPHYSECTOMY; VIRUS HEPATITIS;

ACUTE DISEASE; ADENOMA; ADULT; DRUG-INDUCED LIVER INJURY; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; REMISSION, SPONTANEOUS;

EID: 80053920596     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-009-0173-3     Document Type: Article

References (17)

1. S Melmed 2006 Acromegaly N Engl J Med 355 2558 2573 10.1056/NEJMra062453 17167139 10.1056/NEJMra062453 1:CAS:528:DC%2BD28XhtlWqsbzK (Pubitemid 44917504)
2. PM Stewart 2000 Current therapy for acromegaly Trends Endocrinol Metab 11 128 132 10.1016/S1043-2760(00)00244-7 10754533 10.1016/S1043-2760(00)00244-7 1:CAS:528:DC%2BD3cXivVGiurg%3D (Pubitemid 30238544)
3. I Lancranjan AB Atkinson Sandostatin LAR Group 1999 Results of a European multicentre study with Sandostatin LAR in acromegalic patients Pituitary 1 105 114 10.1023/A:1009980404404 11081188 10.1023/A:1009980404404 1:STN:280:DC%2BD3M%2FlsF2gsA%3D%3D
4. PJ Trainer WM Drake L Katznelson PU Freda V Herman-Bonert AJ van der Lely EV Dimaraki PM Stewart KE Fried ML Vance GM Besser JA Scarlett MO Thorner C Parkinson A Klibanski JS Powell AL Barkan MC Sheppard M Malsonado DR Rose DR Clemmons G Johannsson BA Bengtsson S Stavrou DL Kleinberg DM Cook LS Phillips M Bidlingmaier CJ Strasburger S Hackett K Zib WF Bennett RJ Davis 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant N Engl J Med 342 1171 1177 10.1056/NEJM200004203421604 10770982 10.1056/ NEJM200004203421604 1:CAS:528:DC%2BD3cXjtVOkur4%3D (Pubitemid 30211048)
5. AJ Van der Lely RK Hutson PJ Trainer GM Besser AL Barkan L Katznelson A Klibanski V Herman-Bonert S Melmed ML Vance PU Freda PM Stewart KE Fried DR Clemmons G Johannsson S Stavrou DM Cook LS Phillips CJ Strasburger S Hacker KA Zib RJ Davis JA Scarlett MO Thorner 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormon receptor antagonist Lancet 358 1754 1759 10.1016/S0140-6736(01)06844-1 11734231 10.1016/S0140-6736(01)06844-1 (Pubitemid 33152999)
6. J Feenstra WW de Herder SM ten Have AW van den Beld RA Feelders JAMJL Janssen AJ van der Lely 2005 Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly Lancet 365 1644 1646 10.1016/S0140-6736(05)63011-5 15885297 10.1016/S0140-6736(05)63011-5 1:CAS:528:DC%2BD2MXktVGku7o%3D (Pubitemid 40693415)
7. I Shreiber M Buchfelder M Droste K Forssmann K Mann B Saller CJ Strasburger 2007 Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German pegvisomant observational study Eur J Endocrinol 156 75 82 10.1530/eje.1.02312 10.1530/eje.1.02312 (Pubitemid 46553905)
8. H Biering B Saller J Bauditz M Pirlich B Rudolph A Johne M Buchfelder K Mann M Droste I Schreiber H Lochs CJ Strasburger 2006 Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis Eur J Endocrinol 154 213 220 10.1530/eje.1.02079 16452533 10.1530/eje.1.02079 1:CAS:528:DC%2BD28XitlGltrw%3D
9. J Feenstra MO van Aken WW de Herder RA Feelders AJ van der Lely 2006 Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant Eur J Endocrinol 154 805 806 10.1530/eje.1.02160 16728538 10.1530/eje.1.02160 1:CAS:528:DC%2BD28XmsVKrurc%3D (Pubitemid 43997717)
10. JH Lewis M Ahmed A Shobassy C Palese 2006 Drug-induced liver disease Curr Opin Gastroenterol 22 223 233 10.1097/01.mog.0000218958.40441.fd 16550036 10.1097/01.mog.0000218958.40441.fd (Pubitemid 44090058)
11. SW Lamberts EP Krenning JC Reubi 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors Endocr Rev 12 450 482 10.1210/edrv-12-4-450 1684746 10.1210/edrv-12-4-450 1:CAS:528:DyaK38Xht1SqsbY%3D
12. S Petersenn 2005 Efficacy and limits of somatostatin analogs J Endocrinol Invest 28 Suppl International 53 57 16625846 1:STN:280:DC%2BD283hvV2rsQ%3D%3D
13. U Plöckinger S Albrecht C Mawrin W Saeger M Buchfelder S Petersenn S Schulz 2008 Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas J Clin Endocrinol Metab 93 1203 1210 10.1210/jc.2007-1986 18198230 10.1210/jc.2007-1986 (Pubitemid 351519711)
14. P Maffei C Martini C Pagano N Sicolo F Corbetti 2006 Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant Ann Intern Med 145 4 310 312 16908925 (Pubitemid 46768619)
15. M Marazuela E Dauden E Ocón D Moure L Nattero 2007 Pegvisomant-induced lipohypertrophy: report of a case with histopathology Ann Intern Med 147 10 741 743 18025453 (Pubitemid 351664476)
16. VS Bonert L Kennedy S Petersenn A Barkan J Carmichael S Melmed 2008 Lipodystrophy in patients with acromegaly receiving pegvisomant J Clin Endocrinol Metab 93 9 3515 3518 10.1210/jc.2008-0833 18611977 10.1210/jc.2008-0833 1:CAS:528:DC%2BD1cXhtFChurbN
17. IM Holdaway RC Rajasoorya GD Gamble 2004 Factors influencing mortality in acromegaly J Clin Endocrinol Metab 89 667 674 10.1210/jc.2003-031199 14764779 10.1210/jc.2003-031199 1:CAS:528:DC%2BD2cXhsFOjsLY%3D (Pubitemid 38269875)